STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

Ali Nemati4 days ago23 sec read6 views

French pharmaceutical company Servier acquired Day One Biopharmaceuticals for $2.5 billion, primarily for its approved pediatric brain cancer drug Ojemda, expanding Servier's portfolio in rare cancers. This acquisition underscores the high value placed on innovative treatments for childhood diseases and signals a significant investment in pediatric oncology research and development.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

Heatwaves driving recent 'surge' in compound drought and heat extremes

A recent study indicates that heatwaves are driving a surge in compound drought and heat extremes globally, particularly after global average temperat...A recent study indicates that heatwaves are driving a surge in compound drought and heat extremes globally, particularly after global average temperatures surpassed 14.3°C around the year 2000. The research highlights an intensification of land-atmos...

Ali Nemati

AI & Machine Learning5 days ago22 sec read

Wilbe opens White City lab in London to remove infrastructure bottlenecks for science startups

Wilbe launched its first dedicated lab facility in White City, London, addressing a common challenge for science startups by providing immediate acces...Wilbe launched its first dedicated lab facility in White City, London, addressing a common challenge for science startups by providing immediate access to venture-appropriate lab space. This move supports scientists from training through company buil...

Ali Nemati

Health & MedicineMar 331 sec read

Opinion: STAT+: 6 key dilemmas as human embryo models get ever closer to the real thing

Researchers are developing highly realistic human embryo models using stem cells, which could revolutionize understanding of early human development a...Researchers are developing highly realistic human embryo models using stem cells, which could revolutionize understanding of early human development and disease, as well as tissue sourcing for clinical use. However, this progress raises ethical dilem...

Ali Nemati

AI & Machine LearningMar 325 sec read

FROGENT: An End-to-End Full-process Drug Design Multi-Agent System

FROGENT is a new multi-agent system designed for full-process drug discovery that integrates large language models to automate and unify various stage...FROGENT is a new multi-agent system designed for full-process drug discovery that integrates large language models to automate and unify various stages of drug design, including target identification and molecule generation. This system significantly...

Ali Nemati

AI & Machine LearningMar 321 sec read

MicroVerse: A Preliminary Exploration Toward a Micro-World Simulation

Researchers introduced MicroWorldBench, a benchmark for evaluating microscale simulation tasks in areas like drug discovery and education, revealing c...Researchers introduced MicroWorldBench, a benchmark for evaluating microscale simulation tasks in areas like drug discovery and education, revealing current models' limitations. They also developed MicroVerse, a video generation model that accurately...

Ali Nemati

STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

Related Articles

Heatwaves driving recent 'surge' in compound drought and heat extremes

Wilbe opens White City lab in London to remove infrastructure bottlenecks for science startups

Opinion: STAT+: 6 key dilemmas as human embryo models get ever closer to the real thing

FROGENT: An End-to-End Full-process Drug Design Multi-Agent System

MicroVerse: A Preliminary Exploration Toward a Micro-World Simulation